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Ab

:   antibody

AE

:   asthma exacerbation

altered/LOC

:   altered or loss of consciousness

anorexia/DF

:   anorexia/difficulty feeding

ARI

:   acute respiratory infection

BALF

:   bronchoalveolar lavage fluids

BCL

:   bronchiolitis

CAP

:   community‐acquired pneumonia

CC

:   case‐control

CF

:   cystic fibrosis

CI

:   confidence interval

COH

:   (inception) cohort dataset

CS

:   cross‐sectional

DB

:   difficulty breathing

DFA

:   direct immunofluorescence assay

EIA

:   enzyme immunoassay

EIFA

:   enzyme immunofluorescence assay

ETA

:   endotracheal aspirates

Flu

:   influenza

FS

:   febrile seizure

FRI

:   febrile respiratory illness

HAdV

:   human adenovirus

HBoV‐1

:   human bocavirus type 1

HCoV

:   human coronavirus

HHP‐6

:   human herpesvirus 6

HMPV

:   human metapneumovirus

HPIV

:   human parainfluenza virus

HRV

:   human rhinovirus

IFA

:   (indirect) immunofluorescence assay

ILI

:   influenza‐like illness

LIT

:   literature review dataset

LRTI

:   lower respiratory tract infections

NOS

:   number of studies

NPA

:   nasopharyngeal aspirate

NPS

:   nasopharyngeal swab

NS

:   nasal swabs/secretions

NW

:   nasal washing

OP

:   observational prospective

OPS

:   oropharyngeal swabs

OR

:   observational retrospective

PC

:   prospective cohort

PNA

:   pneumonia

(p)OR

:   (pooled) odds ratio

PPV

:   positive predictive value

PROSPERO

:   International Prospective Register of Systematic Reviews

PS

:   pharyngeal swabs

QI

:   quality improvement

RKI

:   Robert Koch Institute

RS

:   respiratory samples

SARI

:   severe acute respiratory infection

RT

:   rapid test,

RTI

:   respiratory tract infection

TA

:   tracheal aspirates

TS

:   throat swabs

URTI

:   upper respiratory tract infections

WHO

:   World Health Organization

1. INTRODUCTION {#rmv1997-sec-0001}
===============

Influenza and acute respiratory infections (ARI) are major contributors to disease burden in the pediatric age group[1](#rmv1997-bib-0001){ref-type="ref"}, [2](#rmv1997-bib-0002){ref-type="ref"}, [3](#rmv1997-bib-0003){ref-type="ref"}, [4](#rmv1997-bib-0004){ref-type="ref"} with highest mortality rates in resource‐limited settings.[5](#rmv1997-bib-0005){ref-type="ref"}, [6](#rmv1997-bib-0006){ref-type="ref"}

It has been shown that the positive predictive value of a "clinical" influenza diagnosis in children is as low as 32%.[7](#rmv1997-bib-0007){ref-type="ref"} In children in particular, influenza symptoms are often nonspecific, making it difficult to distinguish influenza infection from infection because of other respiratory viruses.[8](#rmv1997-bib-0008){ref-type="ref"} The ability to make accurate "clinical diagnoses" is further hampered by the frequent succession of different respiratorys infection during the winter months.[7](#rmv1997-bib-0007){ref-type="ref"}

For pediatricians in acute care settings, however, it may not always be possible to perform virus diagnostics. Even if diagnostic tests are widely available, presumptive clinical diagnoses will still be influencing clinical decision‐making, such as the use of diagnostics, antivirals, and antibiotics. Clinical bias in the use of diagnostic testing may thus impair epidemiological surveillance and disease burden estimates.[9](#rmv1997-bib-0009){ref-type="ref"}

To address this question further, we explored which clinical features, according to the published literature, may be associated with ARI due to influenza, respiratory syncytial virus (RSV), human adenovirus (HAdV), human rhinovirus (HRV), human metapneumovirus (HMPV), human bocavirus‐1 (HBoV‐1), human parainfluenza virus (HPIV), and human coronavirus (HCoV). We then addressed the same question through analysis of a "real‐world" dataset based on a prospective surveillance of 6073 children aged 0 to 18 years, where detailed clinical presentations and virus diagnoses were assessed and documented in all patients, independent from routine care.[10](#rmv1997-bib-0010){ref-type="ref"}

The objectives of this analysis are as follows: To identify clinical features linked to specific respiratory viral infection in pediatric clinical trials and observational studies published in MedlineTo explore the same question in a real‐world dataset, derived from a pediatric inception cohort.

2. METHODS {#rmv1997-sec-0002}
==========

2.1. Systematic literature review and meta‐analysis {#rmv1997-sec-0003}
---------------------------------------------------

We searched the English language literature published in Medline (PubMed) from January 01, 1996 to March 21, 2017.

The search protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) No. CRD42017059557. The literature search was conducted on March 21, 2017. The search terms are listed in the following online document: <https://www.crd.york.ac.uk/PROSPEROFILES/59557_PROTOCOL_20180419.pdf>

The publications identified by the initial search were included only if (a) study participants were children 0 to 18 years of age; (b) studies were randomized/nonrandomized clinical trials, observational studies, and/or epidemiological reports; (c) ≥1 association between patients with confirmed viral infection and a clinical symptom had been reported; and if (d) a control group with patients testing negatively for the respective viruses was included.

We excluded animal or in vitro studies, adult studies, case series, studies lacking information on clinical features and outcomes, studies lacking virological data, studies lacking same virus‐negative control groups, studies where data could not be reliably categorized and extracted, overlapping studies addressing chronic conditions or other nonrespiratory infection as well as meta‐analyses, review papers, and conference papers.

In the first round of review, the following data were extracted independently: (1) study location (country), (2) study design, (3) age range, (4) cohort size/number of subjects, (5) sampling and laboratory method, and (6) presenting symptoms including respiratory and extrarespiratory symptoms. Full‐text publications were accessed for a second round of review. XM and BR independently reviewed studies against the predefined inclusion and exclusion criteria, and any eligible discrepancy was resolved by discussion among the reviewer team (3 researchers). The clinical symptoms were grouped into the following 19 distinct symptom categories: altered or loss of consciousness (altered/LOC), anorexia/difficulty feeding, apnea, conjunctivitis, cough, hypoxia, diarrhea, dyspnea, fever, headache, malaise, myalgia, rash, rhinitis, seizures, sore throat, signs of upper respiratory tract infection, vomiting, and wheezing/bronchoconstriction/signs of lower respiratory tract infection (henceforth labeled "wheezing").

2.2. Inception cohort analysis {#rmv1997-sec-0004}
------------------------------

The literature review was compared to a well‐described clinical inception cohort[11](#rmv1997-bib-0011){ref-type="ref"}, [12](#rmv1997-bib-0012){ref-type="ref"}, [13](#rmv1997-bib-0013){ref-type="ref"}, [14](#rmv1997-bib-0014){ref-type="ref"}, [15](#rmv1997-bib-0015){ref-type="ref"}: From December 2009 to April 2015, a specifically trained quality improvement (QI) team performed predefined clinical assessments of 6073 influenza‐like illness (ILI) patients aged 0 to 18 years at the point of care.[11](#rmv1997-bib-0011){ref-type="ref"}, [12](#rmv1997-bib-0012){ref-type="ref"}, [13](#rmv1997-bib-0013){ref-type="ref"}, [14](#rmv1997-bib-0014){ref-type="ref"}, [15](#rmv1997-bib-0015){ref-type="ref"} Influenza‐like illness case criteria were defined as evidence of fever with a body temperature ≥38°C and ≥1 respiratory symptom (including cough, rhinitis/coryza, red/sore throat, ear ache, dyspnea, tachypnea, labored breathing, wheezing) or a documented clinician diagnosis of ILI. Clinical assessments were as described previously.[10](#rmv1997-bib-0010){ref-type="ref"} Nasopharyngeal swabs were collected in universal transport medium (Copan™, Copan Diagnostics, Murrieta, CA) and investigated at the National Reference Centre for Influenza at the Robert Koch Institute, Berlin, for 8 respiratory viruses. The QI program was approved by the institutional review board (Charité EA 24/008/10). Informed consent procedures were waived for the purpose of enhanced quality of care and infection control.[10](#rmv1997-bib-0010){ref-type="ref"}, [11](#rmv1997-bib-0011){ref-type="ref"}, [12](#rmv1997-bib-0012){ref-type="ref"}, [13](#rmv1997-bib-0013){ref-type="ref"}, [14](#rmv1997-bib-0014){ref-type="ref"}, [15](#rmv1997-bib-0015){ref-type="ref"}

Nucleic acid was extracted by MagNA Pure 96 DNA and Viral NA Small Volume Kit (Roche Deutschland Holding GmbH, Mannheim, Germany), MagAttract Viral RNA M48 Kit (Qiagen, Hilden, Germany), or RTP DNA/RNA Virus Mini Kit (Invitek, Germany) according to the manufacturer\'s instructions using a specimen volume of 200, 300, and 400 μL, respectively. Twenty‐five microliters of extracted RNA were subjected to cDNA synthesis applying 200 U M‐MLV Reverse Transcriptase (Invitrogen, USA) in a total reaction volume of 40 μL.

Specimens were analyzed for influenza A and B, RSV, HMPV, HAdV, and HRV by real‐time PCR as published previously.[10](#rmv1997-bib-0010){ref-type="ref"}, [11](#rmv1997-bib-0011){ref-type="ref"}, [16](#rmv1997-bib-0016){ref-type="ref"}, [17](#rmv1997-bib-0017){ref-type="ref"}, [18](#rmv1997-bib-0018){ref-type="ref"}, [19](#rmv1997-bib-0019){ref-type="ref"} Investigation of HCoV (NL63, 229E, OC43, and HKU1), HPIV1‐4, and HBoV‐1 was performed in a total reaction volume of 15 μL containing 1× PCR buffer, 4 mM MgCl~2~, 0.2 mM dNTP with dUTP, 40 ng/μL BSA, 0.3 U Platinum Taq Polymerase primers and probes (as specified in [Supporting Information 1](#rmv1997-supitem-0001){ref-type="supplementary-material"}) and 5 μL of cDNA (or nucleic acid for HBoV‐1). Amplification was carried out at 95°C for 300 seconds, followed by 45 cycles at 95°C for 15 seconds and 60°C for 30 seconds.

In summary, the QI program used an unbiased approach where all 19 predefined clinical features were assessed at the point of care, and all 8 viruses were tested in all ILI patients.

2.3. Comparative analysis {#rmv1997-sec-0005}
-------------------------

The comparative statistical analysis was performed using R with the Metaphor Package software.[20](#rmv1997-bib-0020){ref-type="ref"} Clinical features associated with viral pathogens were determined independently using pooled odds ratios (pOR), with 95% confidence intervals (CI) for the literature review dataset (LIT) and odds ratio (OR) for the real‐world (inception cohort) dataset (COH). We used 2 × 2 contingency tables to analyze the association between a virus‐positive (versus virus‐negative) case and an individual clinical feature (present/absent) in the literature and inception cohort, respectively. If lower/upper limits of 95% CI were within 1 decimal point of 1.0, we did not consider these OR as significant.

Random effect models for meta‐analysis were applied.[20](#rmv1997-bib-0020){ref-type="ref"} Heterogeneity testing was done using *I* ^2^ statistics. *I* ^2^ values \<25% were considered low, 25% to 75% as moderate, and values \>75% indicated high levels of heterogeneity.[21](#rmv1997-bib-0021){ref-type="ref"} Publication bias was assessed using funnel plots. A symmetrical plot indicates a lack of publication bias.[22](#rmv1997-bib-0022){ref-type="ref"} For each used OR calculation, we estimated the exact CI using the mid‐p method.[23](#rmv1997-bib-0023){ref-type="ref"}

3. RESULTS {#rmv1997-sec-0006}
==========

3.1. Characteristics of the literature review {#rmv1997-sec-0007}
---------------------------------------------

The initial Medline search yielded 1861 potentially relevant publications. After manual screening of all titles and abstracts, 666 publications were relevant to the topic. Of these, 47 eligible publications were included into the final analysis according to the predefined inclusion and exclusion criteria (Figure [1](#rmv1997-fig-0001){ref-type="fig"}).

![Flow chart describing the systematic literature search and selection of eligible publications](RMV-28-e1997-g001){#rmv1997-fig-0001}

The 47 eligible publications are listed in Table [1](#rmv1997-tbl-0001){ref-type="table"}.[24](#rmv1997-bib-0024){ref-type="ref"}, [25](#rmv1997-bib-0025){ref-type="ref"}, [26](#rmv1997-bib-0026){ref-type="ref"}, [27](#rmv1997-bib-0027){ref-type="ref"}, [28](#rmv1997-bib-0028){ref-type="ref"}, [29](#rmv1997-bib-0029){ref-type="ref"}, [30](#rmv1997-bib-0030){ref-type="ref"}, [31](#rmv1997-bib-0031){ref-type="ref"}, [32](#rmv1997-bib-0032){ref-type="ref"}, [33](#rmv1997-bib-0033){ref-type="ref"}, [34](#rmv1997-bib-0034){ref-type="ref"}, [35](#rmv1997-bib-0035){ref-type="ref"}, [36](#rmv1997-bib-0036){ref-type="ref"}, [37](#rmv1997-bib-0037){ref-type="ref"}, [38](#rmv1997-bib-0038){ref-type="ref"}, [39](#rmv1997-bib-0039){ref-type="ref"}, [40](#rmv1997-bib-0040){ref-type="ref"}, [41](#rmv1997-bib-0041){ref-type="ref"}, [42](#rmv1997-bib-0042){ref-type="ref"}, [43](#rmv1997-bib-0043){ref-type="ref"}, [44](#rmv1997-bib-0044){ref-type="ref"}, [45](#rmv1997-bib-0045){ref-type="ref"}, [46](#rmv1997-bib-0046){ref-type="ref"}, [47](#rmv1997-bib-0047){ref-type="ref"}, [48](#rmv1997-bib-0048){ref-type="ref"}, [49](#rmv1997-bib-0049){ref-type="ref"}, [50](#rmv1997-bib-0050){ref-type="ref"}, [51](#rmv1997-bib-0051){ref-type="ref"}, [52](#rmv1997-bib-0052){ref-type="ref"}, [53](#rmv1997-bib-0053){ref-type="ref"}, [54](#rmv1997-bib-0054){ref-type="ref"}, [55](#rmv1997-bib-0055){ref-type="ref"}, [56](#rmv1997-bib-0056){ref-type="ref"}, [57](#rmv1997-bib-0057){ref-type="ref"}, [58](#rmv1997-bib-0058){ref-type="ref"}, [59](#rmv1997-bib-0059){ref-type="ref"}, [60](#rmv1997-bib-0060){ref-type="ref"}, [61](#rmv1997-bib-0061){ref-type="ref"}, [62](#rmv1997-bib-0062){ref-type="ref"}, [63](#rmv1997-bib-0063){ref-type="ref"}, [64](#rmv1997-bib-0064){ref-type="ref"}, [65](#rmv1997-bib-0065){ref-type="ref"}, [66](#rmv1997-bib-0066){ref-type="ref"}, [67](#rmv1997-bib-0067){ref-type="ref"}, [68](#rmv1997-bib-0068){ref-type="ref"}, [69](#rmv1997-bib-0069){ref-type="ref"}, [70](#rmv1997-bib-0070){ref-type="ref"} One quarter of these studies included children aged 0 to 5 years, and 6.4% and 12.8% of studies recruited children aged 0 to 3 years and aged 0 to 2 years, respectively. The systematic literature review yielded 9960 individual cases of laboratory‐confirmed ARI and 39 898 cases with negative test results for the same virus, respectively. The virology methods varied considerably: PCR was used in the majority of studies (88.9%), followed by enzyme‐linked immunoassays (14.9%), direct/indirect immunofluorescence (21.3%), and culture methods (6.4%). The geographic representation was rather broad, with 34.0% of study subjects stemming from the World Health Organization (WHO) region of the Americas, followed by the European Region (21.3%) and Western Pacific Region (21.3%). Fewer studies represented the WHO African Region (8.5%), the Eastern Mediterranean Region (8.5%), and the Southeast Asian Region (6.4%).

###### 

Characteristics of 47 eligible published studies

  Author, Year, Reference                                       Country        Design      Size    Age                  Sample Type                Type of RTI           Lab Method               Pathogen
  ------------------------------------------------------------- -------------- ----------- ------- -------------------- -------------------------- --------------------- ------------------------ -----------------------------------
  Ahn 2014[24](#rmv1997-bib-0024){ref-type="ref"}               Korea          OP          1528    ≤18 years            NPA                        ARI                   PCR                      HBoV‐1
  Akhras 2010[25](#rmv1997-bib-0025){ref-type="ref"}            USA            OR          256     \<18 years           NPS                        ARI                   DFA, culture, PCR        RSV, HMPV
  Ali 2010[26](#rmv1997-bib-0026){ref-type="ref"}               Jordan         OP          728     \<5 years            NS, TS                     ARI                   PCR                      HMPV
  Annamalay 2016[27](#rmv1997-bib-0027){ref-type="ref"}         Mozambique     OP          277     ≤10 years            NPA                        RTI                   PCR                      HRV
  Bhandary 2016[28](#rmv1997-bib-0028){ref-type="ref"}          India          CS          100     ≤5 years             NPA                        RTI                   DFA                      RSV
  Broor 2014[29](#rmv1997-bib-0029){ref-type="ref"}             USA            OP          245     \<5 years            NS, TS                     ARI                   PCR                      Flu A/B, RSV
  Bryant 2010[30](#rmv1997-bib-0030){ref-type="ref"}            Australia      OP          446     ≤16 years            NPA, NS, TS                ILI                   DFA, PCR                 Flu A
  Carballal 2002[31](#rmv1997-bib-0031){ref-type="ref"}         Argentina      OR          168     \<2 years            NPA                        Acute LRTI            IFA, culture             HAdV
  Chang 2012[32](#rmv1997-bib-0032){ref-type="ref"}             USA            OP and CC   5066    ≤18 years            NS                         ILI                   PCR                      Flu A
  Chano 2005[33](#rmv1997-bib-0033){ref-type="ref"}             Canada         CC          1132    ≤18 years            NPA, BAL, ETA              RTI                   DFA, culture, EIA, PCR   HMPV
  Chen 2010[34](#rmv1997-bib-0034){ref-type="ref"}              China          OP          6296    ≤18 years            NPA                        Acute LRTI            PCR                      RSV, HMPV
  Cuevas 2003[35](#rmv1997-bib-0035){ref-type="ref"}            Brazil         OP          111     \<3 years            NS                         Acute LRTI            PCR                      RSV, HMPV
  Esposito 2016[36](#rmv1997-bib-0036){ref-type="ref"}          Italy          OP          307     ≤18 years            NS                         RTI                   PCR                      HAdV
  Fairchok 2010[37](#rmv1997-bib-0037){ref-type="ref"}          USA            Cohort      318     ≤30 months           NS                         RTI                   PCR                      Flu A
  Farng 2002[38](#rmv1997-bib-0038){ref-type="ref"}             China          OR          48      ≤18 years            TS, serum                  PNA                   IFA                      HAdV
  Fischer Langley 2013[39](#rmv1997-bib-0039){ref-type="ref"}   Guatemala      OP          2413    \<5 years            NPS, OPS                   ARI                   PCR                      RSV
  Flores 2004[40](#rmv1997-bib-0040){ref-type="ref"}            Portugal       OP          225     \<3 years            NS                         Acute BCL             PCR                      RSV
  Giamberardin 2016[41](#rmv1997-bib-0041){ref-type="ref"}      Brazil         CS          250     24‐59 months         NS, OPS                    RTI, asthma           PCR                      Flu A/B, HRV, HAdV, HPIV, HCoV
  Halasa 2015[42](#rmv1997-bib-0042){ref-type="ref"}            Jordan         OP          3173    \<2 years            NS, TS                     RTI, others           PCR                      RSV
  Hite 2007[43](#rmv1997-bib-0043){ref-type="ref"}              UK             CC          411     ≤18 years            NS                         ILI                   RT, culture              Flu A/B
  Hombrouck 2012[44](#rmv1997-bib-0044){ref-type="ref"}         Belgium        OP          139     \<5 years            NPS, TS                    ILI                   PCR                      Flu A, RSV, HRV, HMPV, HPIV
  Hsieh 2014[45](#rmv1997-bib-0045){ref-type="ref"}             China          OP          1062    ≤18 years            Serum                      Flu season            Ab                       Flu A
  Huai 2017[46](#rmv1997-bib-0046){ref-type="ref"}              China          OP          14479   \<15 years           NS                         SARI                  PCR                      Flu A/B
  Jevsnik 2012[47](#rmv1997-bib-0047){ref-type="ref"}           Slovenia       OP          741     \<6 years            NPS, TS, TA, BAL, sputum   ARI                   PCR                      HCoV
  Jin 2010[48](#rmv1997-bib-0048){ref-type="ref"}               China          OP          645     \<16 years           NPA                        ARI                   PCR                      HCoV
  Khamis 2012 [49](#rmv1997-bib-0049){ref-type="ref"}           Oman           OP          259     ≤5 years             RS                         RTI                   PCR                      RSV
  Kuo 2011[50](#rmv1997-bib-0050){ref-type="ref"}               China          CC          308     ≤18 years            NPS, TS                    ILI                   RT, PCR                  Flu A
  Lamarao 2012[51](#rmv1997-bib-0051){ref-type="ref"}           Brazil         CS          1214    ≤18 years            NPS                        CAP                   DFA, PCR                 RSV
  Landa‐Cardena 2012[52](#rmv1997-bib-0052){ref-type="ref"}     Mexico         CS          124     \<6 years            NS                         RTI                   PCR                      HRV
  Leung 2009[53](#rmv1997-bib-0053){ref-type="ref"}             China          OP and OR   1981    \<18 years           NPA                        ARI                   IFA, PCR                 HCoV
  Martin 2015[54](#rmv1997-bib-0054){ref-type="ref"}            Canada         OP          219     ≤2 years             Oral fluid                 HHP‐6 history         PCR                      HBoV‐1
  Moreno‐Valencia 2015[55](#rmv1997-bib-0055){ref-type="ref"}   Mexico         OP          432     \<12 years           NPS                        ARI                   PCR                      Flu A, RSV, HRV, HMPV, HPIV, HAdV
  Nitsch‐Osuch 2013[56](#rmv1997-bib-0056){ref-type="ref"}      Poland         OP          59      ≤59 months           NS, PS                     ILI                   RT, PCR                  Flu A/B
  Nokes 2009[57](#rmv1997-bib-0057){ref-type="ref"}             Kenya          OP          6026    1 day‐59 months      NS                         PNA                   DFA                      RSV
  Nyawanda 2016[58](#rmv1997-bib-0058){ref-type="ref"}          Kenya          OP          4714    \<5 years            NPS, OPS                   ARI                   PCR                      RSV
  Pecchini 2008[59](#rmv1997-bib-0059){ref-type="ref"}          Brazil         OP          455     \<5 years            NPS                        Acute LRTI            IFA                      RSV
  Pierangeli 2012[60](#rmv1997-bib-0060){ref-type="ref"}        Italy          OP          231     ≤16 years            PS, nasal washing          ILI                   PCR                      Flu A, RSV, HRV
  Ramagopal 2016[61](#rmv1997-bib-0061){ref-type="ref"}         India          OP          80      1 month‐3 years      NPS                        BCL                   PCR                      RSV
  Saha 2010[62](#rmv1997-bib-0062){ref-type="ref"}              India          OP          69      10 months‐12 years   NS, TS                     Acute FRI             PCR                      Flu A
  Schuster 2015[63](#rmv1997-bib-0063){ref-type="ref"}          Jordan         OP          3175    \<2 years            NS, TS                     TRI, AE, CF, FS       PCR                      HMPV
  Smit 2012[64](#rmv1997-bib-0064){ref-type="ref"}              Netherlands    OP          423     ≤17 years            OPS, NW                    ILI                   PCR                      Flu A
  Smuts 2011[65](#rmv1997-bib-0065){ref-type="ref"}             South Africa   OP          220     2 months‐5 years     NS                         Cough, DB, wheezing   PCR                      HRV
  Tresoldi 2011[66](#rmv1997-bib-0066){ref-type="ref"}          Brazil         Cohort      61      ≤18 years            NPS, PS                    ILI                   PCR                      Flu A
  von Linstow 2004[67](#rmv1997-bib-0067){ref-type="ref"}       Denmark        OP          374     ≤2 years             NPS                        TRI                   IFA, EIFA, PCR           RSV, HMPV
  Weigl 2003[68](#rmv1997-bib-0068){ref-type="ref"}             Germany        CC          1316    ≤2 years             NPA                        LRTI                  PCR                      RSV
  Yan 2017[69](#rmv1997-bib-0069){ref-type="ref"}               China          OP          387     8 days‐15 years      NPA                        Acute LRTI            PCR                      RSV, HMPV
  Zimmerman 2014[70](#rmv1997-bib-0070){ref-type="ref"}         USA            CC          662     \<2 years            NS, OPS                    URTI                  PCR                      Flu A/B, RSV, HRV, HMPV, HCoV

Ab, antibody; AE, asthma exacerbation; ARI, acute respiratory infection; BALF, bronchoalveolar lavage fluids; BCL, bronchiolitis; CAP, community‐acquired pneumonia; CC, case‐control; CF, cystic fibrosis; CS, cross‐sectional; DB, difficulty breathing; DFA, direct immunofluorescence assay; EIA, enzyme immunoassay; EIFA, enzyme immunofluorescence assay; ETA, endotracheal aspirates; Flu, influenza; FS, febrile seizure; FRI, febrile respiratory illness; HHP‐6, human herpesvirus 6; IFA, (indirect) immunofluorescence assay; ILI, influenza‐like illness; LRTI, lower respiratory tract infection; NPA, nasopharyngeal aspirate; NPS, nasopharyngeal swab; NS, nasal swabs/secretions; NW, nasal washing; OP, observational prospective; OPS, oropharyngeal swabs; OR, observational retrospective; PC, prospective cohort; PNA, pneumonia; PS, pharyngeal swabs; RS, respiratory samples; SARI, severe acute respiratory infection; RT, rapid test; RTI, respiratory tract infection; TA, tracheal aspirates; TS, throat swabs; URTI, upper respiratory tract infection.

3.2. Associations between clinical features and viral infections based on literature review (LIT) {#rmv1997-sec-0008}
-------------------------------------------------------------------------------------------------

### 3.2.1. Fever and wheezing in influenza and RSV infections {#rmv1997-sec-0009}

In clinical practice, fever is often considered a hallmark of influenza disease, whereas wheezing is viewed as "typical" for RSV infections. Therefore, we studied these clinical associations in detail in the published literature (Figures [2](#rmv1997-fig-0002){ref-type="fig"} and [3](#rmv1997-fig-0003){ref-type="fig"}). Of note, the pooled sample sizes in studies of influenza and RSV were highest (N = 24 661 and N = 29 426, respectively). The funnel and forest plots for other significant associations discussed below are provided in the [Supporting Information 2](#rmv1997-supitem-0002){ref-type="supplementary-material"} and [3](#rmv1997-supitem-0003){ref-type="supplementary-material"}.

![Relationship between fever and A, influenza versus B, RSV: LIT forest and funnel plots](RMV-28-e1997-g002){#rmv1997-fig-0002}

![Relationship between wheezing and A, influenza versus B, RSV: LIT forest and funnel plots](RMV-28-e1997-g003){#rmv1997-fig-0003}

Indeed, fever was the single most highly associated feature with regards to influenza infection (pOR = 3.0; 95% CI \[2.0, 4.3\]; *I* ^2^ = 66%) (Figures [2](#rmv1997-fig-0002){ref-type="fig"}A and [4](#rmv1997-fig-0004){ref-type="fig"}A). As evident from detailed literature analysis, most studies agreed on a *positive correlation*, with 1 exception.[66](#rmv1997-bib-0066){ref-type="ref"} No evidence of publication bias was observed. There was no significant association in the meta‐analysis between fever and RSV (pOR 1.1; 95% CI \[0.9, 1.3\]; *I* ^2^ = 76%), albeit individual studies suggested (positive or negative) associations (Figure [2](#rmv1997-fig-0002){ref-type="fig"}B).

![Summary of statistically significant (*P* \< .05) features identified in A, the LIT dataset and in B, the COH dataset. ★ 95% CI exceeding scale: for seizure/HMPV, OR (95% CI) =16.6 (0.6, 438.1) and for or diarrhea/HAdV OR (95% CI) OR = 14.4 (2.5, 82.1)](RMV-28-e1997-g004){#rmv1997-fig-0004}

The meta‐analysis (Figure [3](#rmv1997-fig-0003){ref-type="fig"}B) also yielded a significant association between wheezing and RSV infection (pOR = 2.2; 95% CI \[1.7, 2.8\]; *I* ^2^ = 86%). In‐depth analysis of individual studies showed positive associations for most RSV studies, with 2 exceptions.[35](#rmv1997-bib-0035){ref-type="ref"}, [40](#rmv1997-bib-0040){ref-type="ref"} There was some publication bias in the RSV studies. Of note, wheezing was *not* significantly associated with influenza (pOR = 1.0; 95% CI \[0.7, 1.4\]; *I* ^2^ = 35%) (Figure [3](#rmv1997-fig-0003){ref-type="fig"}A).

### 3.2.2. Clinical associations across all types of respiratory infection {#rmv1997-sec-0010}

Associations with fever or wheezing however are neither unique to influenza nor to RSV. When we studied the meta‐analyses across all 8 types of respiratory viral infection, multiple overlapping associations were easily identified for different types of respiratory viral infections (Figure [4](#rmv1997-fig-0004){ref-type="fig"}A). In fact, most associations were shared across multiple types of viral infection, and no clinical feature stood out as unique to any specific type of infection.

In addition to influenza, fever was also significantly associated with HMPV (pOR = 1.7; 95% CI \[1.2, 2.3\]; *I* ^2^ = 45%) and HAdV infections (pOR = 2.2; 95% CI \[1.2, 4.1\]; *I* ^2^ = 11%). Additional features significantly associated with influenza infection included malaise (pOR = 2.4; 95% CI \[1.5, 4.0\]; *I* ^2^ = 48%), headache (pOR = 1.9; 95% CI \[1.2, 3.3\]; *I* ^2^ = 76%), cough (pOR = 1.6; 95% CI \[1.3, 2.0\]; *I* ^2^ = 19%), and rhinitis (pOR = 1.4; 95% CI \[1.3, 1.6\]; *I* ^2^ = 0%).

Wheezing was not only linked to RSV infections but also to HMPV (pOR = 1.6; 95% CI \[1.1, 2.2\]; *I* ^2^ = 54%) and HBoV‐1 infections (pOR = 1.4; 95% CI \[1.1, 2.0\]; *I* ^2^ = 0%). The strongest association with RSV infection in the literature was seen with cough and dyspnea (pOR~cough~ = 2.9; 95% CI \[1.8, 4.6\]; *I* ^2^ = 77% and pOR~dyspnea~ = 2.3; 95% CI \[1.7, 3.0\]; *I* ^2^ = 84%). Cough and dyspnea were also shared with HMPV infection (pOR~cough~ = 4.6; 95% CI \[2.5, 8.6\]; *I* ^2^ = 18% and pOR~dyspnea~ = 1.7; 95% CI \[1.1, 2.4\]; *I* ^2^ = 39%), and cough was also linked to influenza and HBoV‐1 infections.

3.3. New associations revealed in the inception cohort (COH) {#rmv1997-sec-0011}
------------------------------------------------------------

The same clinical features were now tested in the clinical cohort (Figure [4](#rmv1997-fig-0004){ref-type="fig"}B). The most striking difference was that associations in the COH dataset yielded narrower CI compared to the LIT dataset.

Several new (positive and negative) associations were revealed in the COH dataset that were not previously observed in the meta‐analysis. For example, influenza was positively linked to myalgia (OR 3.1; 95% CI \[2.3, 4.3\]) and sore throat (OR = 1.8; 95% CI \[1.5, 2.1\]). Wheezing (OR = 0.4; 95% CI \[0.3, 0.5\]) as well as hypoxia (OR = 0.4; 95% CI \[0.4, 0.6\]), dyspnea (OR = 0.5; 95% CI \[0.4, 0.6\]), rash, and diarrhea (both OR = 0.7; 95% CI \[0.6, 0.9\]) were *negatively* linked to influenza in the COH dataset.

With respect to RSV, anorexia/difficulty feeding and apnea were positively linked to that pathogen (OR = 1.6; 95% CI \[1.4, 1.8\] and OR = 1.5; 95% CI \[1.1, 2.1\] respectively). Additional *negative* associations were also revealed for RSV, namely fever (OR = 0.5; 95% CI \[0.4, 0.6\]), headache and myalgia (OR = 0.2; 95% CI \[0.1, 0.2\] and OR = 0.2; 95% CI \[0.1, 0.3\] respectively), seizures (OR = 0.4; 95% CI \[0.3, 0.5\]), rash, and sore throat (OR = 0.8; 95% CI \[0.6, 0.9\] and OR = 0.8; 95% CI \[0.7, 0.9\], respectively).

Of note, headache was *negatively* associated with all respiratory viral infections, except for influenza.

3.4. Agreements and disagreements between literature and cohort data (LIT/COH) {#rmv1997-sec-0012}
------------------------------------------------------------------------------

Figure [5](#rmv1997-fig-0005){ref-type="fig"} provides a "matrix view" of clinical features in relation to the 8 different types of viral infection, in direct comparison between LIT and COH data. This synopsis confirms that in most instances, COH data agreed with published literature trends, usually with higher OR and higher confidence levels (ie, narrower 95% CI) despite a smaller sample size. Exceptions were malaise/influenza, fever/HMPV, vomiting/HRV, and malaise/HAdV, which could not be confirmed in the COH data.

![Comparison between literature review (LIT; pOR) and cohort data (COH; OR): Dark green color: positive agreement with statistically significant positive associations in both LIT and COH datasets. Dark red color: negative agreement with statistically significant negative associations in LIT and COH. Light green color: significant positive association in either LIT or COH, but not the other; light red color: significant negative association in either LIT or COH, but not the other; gray color: borderline‐significant associations (ie, CI values close to 1). N: number of study subjects with diagnostic testing and clinical data](RMV-28-e1997-g005){#rmv1997-fig-0005}

The matrix view in Figure [5](#rmv1997-fig-0005){ref-type="fig"} also provides an overview of new *negative (red)* as well as *positive (green)* associations in the COH column/analysis that were not evident in the LIT column/analysis. Individual clinical features were not distinctive but shared among multiple types of viral infection, even if OR were not always significant.

The synopsis of meta‐analysis and inception cohort suggests that fever is significantly associated with influenza and HAdV infections, but again, the presence of fever does not rule out any of the other types of viral infection. HAdV infections were also linked to diarrhea. Cough is most likely present in influenza, RSV, HMPV, and HBOV‐1 infections but also observed in other respiratory infections. Wheezing was most prominent in RSV, HMPV, and HBOV‐1 infections. Wheezing was less likely to be seen in influenza and HAdV infections in the cohort, whereas the literature review revealed inconclusive results in this regard. HCoV infections showed no agreement bewteen LIT and COH datasets with no data available in the literature on a number of nonrespiratory symptoms. The only negative association confirmed in both LIT and COH datasets was between malaise and HRV infections.

4. DISCUSSION {#rmv1997-sec-0013}
=============

We are presenting the first systematic literature review and meta‐analysis coupled with the analysis of a matching inception cohort, addressing the question whether respiratory viral infections in children can be differentiated based on individual clinical features. The prospective cohort confirmed several trends that were also identified in the meta‐analysis of the published literature. But the cohort dataset also established new significant associations between individual clinical features and viral infections.

Our matching analysis showed that systemic signs and symptoms such as fever and headache are more common in influenza and HAdV infections, whereas RSV, HMPV, and HBoV‐1 are more likely to manifest with respiratory symptoms such as wheezing, cough, and dyspnea. This trend was observed in the meta‐analysis and confirmed in the inception cohort. The approach of linking individual clinical features to specific viral infections however revealed a major diagnostic challenge to the clinician: None of the associations identified with either method were unique to any specific type of respiratory viral infection, but were shared across several types of infection. Individual clinical signs or symptoms can therefore *not* be used to reliably rule‐in or rule‐out any specific type of respiratory viral infection. For the time being, physicians need to be aware that clinical diagnoses are insufficiently sensitive, and laboratory testing will remain inevitable.

The results in our matched analysis are broadly in line with literature reviews by Ebell et al[71](#rmv1997-bib-0071){ref-type="ref"} confirming the suspected association between fever and influenza. The findings by Ebell et al[71](#rmv1997-bib-0071){ref-type="ref"} however are limited by the fact that viruses other than influenza (such as adenoviruses for example) were not studied. Thornton et al,[72](#rmv1997-bib-0072){ref-type="ref"} the second literature review in this area, found that wheezing is associated with RSV infections, but this study again lacked associations with other respiratory viral pathogens tested in this study (such as HMPV and HBoV‐1). The latter also differed from the current study in that it was restricted to children with acute cough. Compared to previous reviews, our meta‐analysis included more recent literature sources and lager sample sizes (49 858 versus 6790 and 15 069, respectively) and a slightly greater number of countries (24 versus 4 and 20, respectively). This current meta‐analysis is also the only one linking to a prospective dataset.

Overall, literature data on RSV and influenza (and to a lesser degree, HMPV) seemed more readily available than literature on other respiratory viruses, which remain understudied in children. With the advent of new vaccines and antivirals against various respiratory viruses however, it will soon become critical to distinguish respiratory viral infections and to study the associated disease burden, including in the acute care setting.

The individual studies in our meta‐analysis showed high levels of heterogeneity, especially with regards to inclusion criteria and/or cutoff criteria for specific symptoms such as fever and hypoxia. For instance, 7 studies used a hypoxia definition of oxygen saturation \<90% while 2 studies used higher thresholds of \<92%[29](#rmv1997-bib-0029){ref-type="ref"} and \<95%[60](#rmv1997-bib-0060){ref-type="ref"}. Similarly, 11 studies defined fever as body temperature ≥38°C, 6 studies used cutoff values at 37.5°C,^27,35,37,40,52,65^ and 1 study 38.2°C[73](#rmv1997-bib-0073){ref-type="ref"}, while 22 studies did not define fever at all. Various clinical data collection methods, including phone interviews[24](#rmv1997-bib-0024){ref-type="ref"}, [29](#rmv1997-bib-0029){ref-type="ref"}, [37](#rmv1997-bib-0037){ref-type="ref"}, [39](#rmv1997-bib-0039){ref-type="ref"}, [41](#rmv1997-bib-0041){ref-type="ref"} questionnaires,[26](#rmv1997-bib-0026){ref-type="ref"}, [27](#rmv1997-bib-0027){ref-type="ref"}, [36](#rmv1997-bib-0036){ref-type="ref"}, [40](#rmv1997-bib-0040){ref-type="ref"}, [45](#rmv1997-bib-0045){ref-type="ref"}, [49](#rmv1997-bib-0049){ref-type="ref"}, [52](#rmv1997-bib-0052){ref-type="ref"}, [58](#rmv1997-bib-0058){ref-type="ref"}, [68](#rmv1997-bib-0068){ref-type="ref"} and surveys,^70^ were used to obtain information on clinical features; clinical data collection for these studies may thus have been subject to recall bias, interviewer bias, or misclassification bias. Additional issues may arise in the design of control groups in observational and cohort studies[33](#rmv1997-bib-0033){ref-type="ref"}, [68](#rmv1997-bib-0068){ref-type="ref"}, [70](#rmv1997-bib-0070){ref-type="ref"} Among 6 case‐control studies, merely 2 used age‐matched or sex‐matched control groups[43](#rmv1997-bib-0043){ref-type="ref"}, [73](#rmv1997-bib-0073){ref-type="ref"} and 1 was randomized.^50^ Publication bias was also of concern in literature studies as funnel plots indicate that negative associations may have been missed in the published literature.

By contrast, the design of the inception cohort limited the risk of bias and heterogeneity through standardized clinical assessments in a predefined group of patients followed by independent laboratory and data analysis. In inception cohorts, the same data are solicited from all patients, and the same definitions/cutoff criteria for symptoms such as fever and hypoxia are used consistently. Standardized clinical and laboratory data collection in the QI program included predefined positive and negative findings, yielding a complete dataset for the analysis of positive and negative associations. Commonly referenced symptoms such as headache and myalgia may be underreported in infants and toddlers compared to older children. Headache and myalgia can only be elicited when age‐appropriate examination techniques are applied. To avoid observer bias in the inception cohort, a trained QI team elicited these symptoms accurately in all patients, regardless of age.

In clinical routine care in most settings, it will not be feasible to obtain virus diagnostics on the 8 most common respiratory viral pathogens in all patients with ILI, as was the case in this inception cohort. However, it will be important for clinicians to be conscious of awareness bias. One of the greatest challenges may lie in preconceived notions of "typical clinical presentations" in children with specific viral infections. The literature analysis may have revealed some of these inherent biases.

Clinical judgment is not only influenced by the lecture of journal articles: One may speculate that textbook knowledge (as acquired during medical school and residency training) also influences clinical decision‐making. The most commonly referenced pediatric textbook (Nelson\'s textbook of pediatrics), for example, states that influenza infection is dominated by systemic symptoms such as fever, myalgia, chills, headache, malaise, and anorexia.[74](#rmv1997-bib-0074){ref-type="ref"} It also suggests that the onset of RSV infections is associated with rhinorrhea, cough, and wheezing, sometimes concomitant with a low‐grade fever.[75](#rmv1997-bib-0075){ref-type="ref"} For these 2 diseases however, there are no literature references provided, nor specific guidance on the differential diagnosis in clinical practice. Nelson\'s textbook also states that symptoms of HAdV infection may be difficult to distinguish from similar illnesses caused by other pathogens, such as RSV, HPMV, or HRV.[76](#rmv1997-bib-0076){ref-type="ref"} However, it does not mention the difficulty in differentiating influenza infections from HAdV and other respiratory viral infections in children, as identified in the current work.

It may be of interest that the mass media have recently picked up on the fact that "not all that looks like the flu may indeed be influenza": Media reports by CNN, NBC News, and New York Daily News during the recent flu season emphasized that adenovirus infections may mimic symptoms otherwise attributed to influenza.[77](#rmv1997-bib-0077){ref-type="ref"}, [78](#rmv1997-bib-0078){ref-type="ref"}, [79](#rmv1997-bib-0079){ref-type="ref"} This recent media attention underlines the importance of health messages to the general public, for example to avoid the false impression that "flu vaccines don\'t work."

The current work has several strengths and limitations. The systematic review was restricted to publications in English and available in PubMed. Articles published elsewhere may have been missed. PubMed and the English language were chosen as they represent the most commonly accessed publications by clinicians.

A total of 205 literature studies had to be excluded because of lack of a "virus‐negative" control groups (Figure [1](#rmv1997-fig-0001){ref-type="fig"}). In the inception cohort, each patient was simultaneously tested (+/−) for the same viral pathogens using highly sensitive and specific RT‐PCR assays at the National Reference Centre for Influenza at the Robert‐Koch Institute. Even though sample sizes were usually smaller in the inception cohort, prospective data collection resulted in higher confidence levels, because of a comprehensive dataset with predefined variables (8 viruses/19 clinical features) determined in all subjects.

The inception cohort dataset was derived from a single center and 6073 subjects, limiting the generalizability of these findings to other settings with different patient populations or health care systems. The literature meta‐analysis was more global in reach. Overall, cohort sizes were higher in the literature meta‐analysis focusing on influenza (N = 24661), RSV (N = 29462), and HMPV (N = 14010).

As mentioned above, the available literature data on HRV, HAdV, HPIV, and HBoV‐1 infections in children are relatively sparse, with sample sizes ranging from 1139 for HPIV to 2653 for HRV indicating selection bias. Published articles often focused on no more than 1 to 3 viral pathogens at a time and optional reporting of symptoms. The literature review is also limited by the inconsistency of laboratory methods used to detect respiratory viruses: Each published study used slightly different laboratory methods. In the inception cohort, a trained QI team obtained clinical specimens and delivered these to 1 National Reference Center.

Lastly, the effect of antiviral treatment or vaccination status on clinical features was not assessed in this analysis. Among the 6073 patients included in the inception cohort, only 3.3% received antivirals and influenza vaccination rates were 8.2% (data not shown). Future prospective studies or QI programs in different settings (for example in countries with universal influenza vaccination and treatment recommendations) may allow for the analysis of medical interventions.[80](#rmv1997-bib-0080){ref-type="ref"}

5. CONCLUSIONS {#rmv1997-sec-0014}
==============

We showed that point‐of‐care clinical assessments via mobile application represent a powerful mechanism to identify "typical clinical features" likely to be associated with a specific viral infection.

Many clinical features are shared across different types of respiratory viral infection. This means that even though significant associations between individual clinical features and viral infections have been identified, clinical symptoms alone cannot be used to predict specific respiratory viral infections in a particular patient. Clinicians should be aware that clinical features alone will not "rule‐in" or "rule‐out" any specific type of viral infection. Diagnostic testing for respiratory viruses will remain the cornerstone of accurate diagnoses. Testing should be encouraged to prevent unnecessary prescriptions of antivirals in "similar‐looking" noninfluenza cases, where neuraminidase inhibitors would be ineffective.[81](#rmv1997-bib-0081){ref-type="ref"}, [82](#rmv1997-bib-0082){ref-type="ref"}

Methodologically, prospective data collection may be more effective in identifying clinical associations than large‐scale meta‐analyses of the medical literature. While some trends in the literature are confirmed, additional features were identified through the inception cohort. In the future, complex decision models considering combinations of symptoms rather than individual features may be more useful to inform best practice. Machine‐learning algorithms may show the way toward "smart" decision software and the targeted use of diagnostics and antivirals.
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